Cytosorbents (CTSO) Return on Capital Employed (2011 - 2026)

Cytosorbents has reported Return on Capital Employed for 15 years, with the latest figure at 53.34% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1348.0% year-over-year to 53.34%; the trailing twelve-month figure through Mar 2026 stood at 53.34% (down 1348.0% YoY), and the FY2025 full-year result was 40.89%, down 11.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 53.34%, down from 41.84% in the prior quarter.
• The five-year high for Return on Capital Employed was 37.43% in Q3 2025, with the low at 86.14% in Q4 2023.
• Historically, Return on Capital Employed has averaged 55.27% across 5 years, with a median of 53.34% in 2026.
• Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 4285 bps — and 2024, when it surged 4258 bps.
• Cytosorbents' Return on Capital Employed stood at 59.43% in 2022, then tumbled by 45 bps to 86.14% in 2023, then jumped by 49 bps to 43.56% in 2024, then increased by 4 bps to 41.84% in 2025, then retreated by 28 bps to 53.34% in 2026.
• The last three Return on Capital Employed figures came in at 53.34% (Q1 2026), 41.84% (Q4 2025), and 37.43% (Q3 2025), per Business Quant data.